Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
Cost of revenue | ||||||||||
Gross profit | ||||||||||
Operating expense | 2.82%10.82M | 194.75%4.3M | -51.77%1.51M | -25.50%2.23M | -5.40%2.78M | -20.04%10.52M | -56.00%1.46M | -8.43%3.13M | -16.16%2.99M | 2.94%2.94M |
Selling and administrative expenses | 38.24%7.63M | 316.51%3.66M | -52.24%714.57K | -5.01%1.51M | 12.34%1.74M | -16.45%5.52M | -46.76%878.43K | -5.72%1.5M | -7.53%1.59M | -5.74%1.55M |
-Selling and marketing expense | -30.41%571.04K | -41.64%86.27K | -65.83%83.16K | -34.23%162.95K | 31.41%238.66K | -42.58%820.55K | -54.76%147.83K | -42.12%243.33K | -27.56%247.77K | -46.57%181.62K |
-General and administrative expense | 50.24%7.06M | 388.99%3.57M | -49.60%631.41K | 0.37%1.35M | 9.80%1.5M | -9.23%4.7M | -44.79%730.6K | 7.41%1.25M | -2.57%1.35M | 4.92%1.37M |
Research and development costs | -36.24%3.19M | 10.12%637.96K | -51.35%794.44K | -48.84%716.37K | -25.14%1.04M | -23.66%5M | -65.17%579.35K | -10.79%1.63M | -24.21%1.4M | 14.70%1.39M |
Operating profit | -2.82%-10.82M | -194.75%-4.3M | 51.77%-1.51M | 25.50%-2.23M | 5.40%-2.78M | 20.04%-10.52M | 56.00%-1.46M | 8.43%-3.13M | 16.16%-2.99M | -2.94%-2.94M |
Net non-operating interest income expense | -7.32M | 0 | -7.32M | |||||||
Total other finance cost | --7.32M | --0 | --7.32M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Other net income (expense) | 1,340.41%6.63M | 8,513.15%147.74K | 22,852.63%6.48M | -99.61%1.7K | 241.63%4.84K | 2,238.51%460.49K | -107.38%-1.76K | 222.66%28.23K | 2,357.84%437.43K | -16.54%-3.42K |
Gain on sale of security | --6.52M | --111.32K | --6.41M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Other non- operating income (expenses) | -76.44%108.48K | 2,173.75%36.42K | 132.15%65.53K | -99.61%1.7K | 241.63%4.84K | 2,238.51%460.49K | -107.38%-1.76K | 222.66%28.23K | 2,357.84%437.43K | -16.54%-3.42K |
Income before tax | -14.39%-11.51M | -184.27%-4.15M | 24.08%-2.35M | 12.83%-2.23M | 5.68%-2.78M | 23.67%-10.06M | 55.63%-1.46M | 9.87%-3.1M | 28.79%-2.56M | -2.96%-2.94M |
Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income | -14.39%-11.51M | -184.27%-4.15M | 24.08%-2.35M | 12.83%-2.23M | 5.68%-2.78M | 23.67%-10.06M | 55.63%-1.46M | 9.87%-3.1M | 28.79%-2.56M | -2.96%-2.94M |
Net income continuous Operations | -14.39%-11.51M | -184.27%-4.15M | 24.08%-2.35M | 12.83%-2.23M | 5.68%-2.78M | 23.67%-10.06M | 55.63%-1.46M | 9.87%-3.1M | 28.79%-2.56M | -2.96%-2.94M |
Minority interest income | ||||||||||
Net income attributable to the parent company | -14.39%-11.51M | -184.27%-4.15M | 24.08%-2.35M | 12.83%-2.23M | 5.68%-2.78M | 23.67%-10.06M | 55.63%-1.46M | 9.87%-3.1M | 28.79%-2.56M | -2.96%-2.94M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -14.39%-11.51M | -184.27%-4.15M | 24.08%-2.35M | 12.83%-2.23M | 5.68%-2.78M | 23.67%-10.06M | 55.63%-1.46M | 9.87%-3.1M | 28.79%-2.56M | -2.96%-2.94M |
Basic earnings per share | 97.94%-56.94 | 91.77%-7.7276 | 99.38%-4.4013 | 81.40%-140 | 72.04%-455 | 65.33%-2.77K | 94.79%-93.87 | 62.98%-706.2 | 63.25%-752.5 | 30.08%-1.63K |
Diluted earnings per share | 97.94%-56.94 | 91.77%-7.7276 | 99.38%-4.4013 | 81.40%-140 | 72.04%-455 | 65.33%-2.77K | 94.79%-93.87 | 62.98%-706.2 | 63.25%-752.5 | 30.08%-1.63K |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |